Sizheng Steven Zhao, MBChB, PhD
Credit: LinkedIn
JAK inhibitor (JAKi) therapy was not associated with an increased risk of cardiovascular disease, venous thromboembolism (VTE), or some cancers in people with psoriatic arthritis (PsA) and spondyloarthritis (SpA) compared to TNF inhibitors (TNFi) or IL-17 inhibitors (IL-17i).1
“Compared to TNFi, tofacitinib was shown to increase risk of CVD and cancer among people with rheumatoid arthritis (RA) with risk of CVD. Although JAKi are widely used in SpA, their safety profile remains unclear. Risk profiles may differ among SpA patients who are typically younger and have lower systemic inflammatory burden,” lead investigator Sizheng Steven Zhao, MBChB, PhD, Clinical Lecturer at the Centre for Musculoskeletal Research, University of Manchester, United Kingdom, and colleagues…